The challenge
The client sought to accelerate growth by expanding into adjacent therapeutic areas but lacked a cohesive framework to evaluate its diverse R&D initiatives. Resource allocation decisions were fragmented, leading to concerns that investment was diffused across too many lower-impact projects. Leadership needed a structured view of which technology platforms and market opportunities offered the greatest potential to drive long-term differentiation.
The solution
BCE applied a structured innovation portfolio framework that integrated external market attractiveness, internal capability readiness, and technical and clinical feasibility. The team modeled potential adoption pathways, benchmarked competing technologies, and used decision-analytic tools to evaluate each program’s impact, risk, and strategic fit. This created a unified fact base to support cross-functional alignment.
The results
BCE delivered a prioritized R&D portfolio roadmap that clarified which initiatives should be advanced, which warranted partnership exploration, and which required future validation. The roadmap equipped leadership with transparent decision criteria to guide investment and focus resources on innovation areas with the strongest long-term potential.
